Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:GBT's Cash-to-Debt is ranked higher than
66% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:GBT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GBT' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
NAS:GBT's Interest Coverage is ranked higher than
57% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. NAS:GBT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:GBT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 3
Altman Z-Score: 41.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -39.65
NAS:GBT's ROE % is ranked higher than
50% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:GBT: -39.65 )
Ranked among companies with meaningful ROE % only.
NAS:GBT' s ROE % Range Over the Past 10 Years
Min: -110.51  Med: -80.47 Max: -39.65
Current: -39.65
-110.51
-39.65
ROA % -37.19
NAS:GBT's ROA % is ranked lower than
53% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:GBT: -37.19 )
Ranked among companies with meaningful ROA % only.
NAS:GBT' s ROA % Range Over the Past 10 Years
Min: -293.52  Med: -56.87 Max: -37.19
Current: -37.19
-293.52
-37.19
ROC (Joel Greenblatt) % -3186.68
NAS:GBT's ROC (Joel Greenblatt) % is ranked lower than
75% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:GBT: -3186.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:GBT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -3666.83  Med: -1588.74 Max: -662
Current: -3186.68
-3666.83
-662
GuruFocus has detected 2 Warning Signs with Global Blood Therapeutics Inc NAS:GBT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GBT's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

GBT Guru Trades in Q3 2016

Jim Simons 101,200 sh (New)
Paul Tudor Jones Sold Out
» More
Q4 2016

GBT Guru Trades in Q4 2016

Jim Simons Sold Out
» More
Q1 2017

GBT Guru Trades in Q1 2017

Steven Cohen 411,100 sh (New)
» More
Q2 2017

GBT Guru Trades in Q2 2017

Paul Tudor Jones 21,705 sh (New)
Steven Cohen 698,766 sh (+69.97%)
» More
» Details

Insider Trades

Latest Guru Trades with GBT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325411    SIC: 2834
Compare:NAS:DVAX, NAS:AIMT, NAS:LXRX, SZSE:000403, SHSE:603718, SZSE:300255, NYSE:CO, XSWX:SFZN, XTER:BIO3, SZSE:002022, NAS:ESPR, TSE:4565, NAS:SGMO, SZSE:000518, NAS:ZLAB, NYSE:BHVN, NAS:ASND, OCSE:BAVA, SZSE:300204, XKRX:005250 » details
Traded in other countries:G5B.Germany,
Headquarter Location:USA
Global Blood Therapeutics Inc is a clinical-stage biopharmaceutical company in the United States. Its major focus lies on developing therapeutics for the treatment of blood-based disorders such as red blood cell sickling.

Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.

Top Ranked Articles about Global Blood Therapeutics Inc

Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
Steven Cohen Doubles Down on Sickle Cell Disease Therapeutics Company Global Blood Guru adds approximately 225% to the position
On Oct. 2, Steven Cohen (Trades, Portfolio) increased his Global Blood Therapeutics Inc. (NASDAQ:GBT) position, according to GuruFocus real-time picks. Read more...
Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October
Global Blood Therapeutics Announces New Employment Inducement Grants
Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference
Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD)
Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September
Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference
Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results
Global Blood Therapeutics Announces New Employment Inducement Grants

Ratios

vs
industry
vs
history
PB Ratio 4.98
GBT's PB Ratio is ranked lower than
57% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. GBT: 4.98 )
Ranked among companies with meaningful PB Ratio only.
GBT' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 7.36
Current: 4.98
0
7.36
EV-to-EBIT -12.32
GBT's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. GBT: -12.32 )
Ranked among companies with meaningful EV-to-EBIT only.
GBT' s EV-to-EBIT Range Over the Past 10 Years
Min: -19.24  Med: 0 Max: 0
Current: -12.32
-19.24
0
EV-to-EBITDA -12.49
GBT's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. GBT: -12.49 )
Ranked among companies with meaningful EV-to-EBITDA only.
GBT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.55  Med: 0 Max: 0
Current: -12.49
-19.55
0
Current Ratio 13.70
GBT's Current Ratio is ranked higher than
87% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. GBT: 13.70 )
Ranked among companies with meaningful Current Ratio only.
GBT' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 14.63 Max: 24.45
Current: 13.7
0.99
24.45
Quick Ratio 13.70
GBT's Quick Ratio is ranked higher than
87% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. GBT: 13.70 )
Ranked among companies with meaningful Quick Ratio only.
GBT' s Quick Ratio Range Over the Past 10 Years
Min: 0.99  Med: 14.63 Max: 24.45
Current: 13.7
0.99
24.45

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 6.70
GBT's Price-to-Net-Cash is ranked higher than
57% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. GBT: 6.70 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GBT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.75  Med: 4.88 Max: 8.53
Current: 6.7
2.75
8.53
Price-to-Net-Current-Asset-Value 6.53
GBT's Price-to-Net-Current-Asset-Value is ranked higher than
55% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. GBT: 6.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GBT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.72  Med: 4.78 Max: 8.42
Current: 6.53
2.72
8.42
Price-to-Tangible-Book 4.98
GBT's Price-to-Tangible-Book is ranked higher than
52% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. GBT: 4.98 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GBT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.69  Med: 4.1 Max: 8.29
Current: 4.98
2.69
8.29
Earnings Yield (Greenblatt) % -8.12
GBT's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. GBT: -8.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GBT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -266.48  Med: 0 Max: 0
Current: -8.12
-266.48
0

More Statistics

EPS (TTM) $ -2.49
Short Percentage of Float18.40%
52-Week Range $13.35 - 41.15
Shares Outstanding (Mil)43.68

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $)
EPS ($) -2.34 -2.83 -2.79 -1.19
EPS without NRI ($) -2.34 -2.83 -2.79 -1.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
37.00%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}